The largest biotech rounds of 2026 and the investors behind them (April 1 - September 12, 2026)

Why this list is different

Of the 45 largest health deals, only 15 were startup rounds. The rest: 15 debt, 10 other (corporate deals with buyout options, SPAC mergers, revenue-share financing), 4 acquisitions and PE, 1 unverified.

Method

Biotech startup rounds announced from April 1 to September 12, 2026, ranked by announced amount. Every round was checked against a company or press announcement. Digital health companies are in a separate list. Debt, acquisitions, PE deals, IPOs and SPAC mergers, corporate deals with buyout options and revenue-share financing are left out.

The 10 largest rounds

The rounds

1. Isomorphic Labs: $2.1B, Series B

In short: AI drug discovery company spun out of Google DeepMind. On May 12, 2026 it announced a $2.1B Series B. Lead investor: Thrive Capital. Other investors in the round include Alphabet, GV, CapitalG, MGX and Temasek. Source

2. NewLimit: $435M, Series C

In short: Longevity biotech developing epigenetic therapies to reverse cellular aging. On June 2, 2026 it announced a $435M Series C. Lead investor: Founders Fund. Other investors in the round include Kleiner Perkins, Thrive Capital, Greenoaks, Quiet Capital and Eli Lilly Ventures. Source

3. Chai Discovery: $400M, Series C

In short: AI models that design antibodies and other drug molecules. On July 14, 2026 it announced a $400M Series C. Lead investor: Index Ventures. Other investors in the round include Kleiner Perkins, Sequoia Capital, Dimension, Thrive Capital and OpenAI. Source

4. Ollin Biosciences: $330M, Series B

In short: Austin biotech developing antibodies for diabetic macular edema and wet AMD. On June 23, 2026 it announced a $330M Series B. Lead investors: TCGX and ARCH Venture Partners. Other investors in the round include RA Capital Management, a16z Bio + Health, CPP Investments, Mubadala Capital and Blackstone Multi-Asset Investing. Source

5. AdvanCell: $315M, Series D

In short: Developer of lead-212 targeted alpha radiotherapies for prostate and other cancers. On July 15, 2026 it announced a $315M Series D. Lead investors: Ally Bridge Group and Alpha Wave. Other investors in the round include Bain Capital Life Sciences, Fidelity Management & Research, T. Rowe Price, Eli Lilly and Sanofi Ventures. Source

6. Beeline Medicines: $300M, Series A

In short: Immunology biotech developing five autoimmune drug programs licensed from BMS. On April 15, 2026 it announced a $300M Series A. Lead investor: Bain Capital. CPP Investments and Bristol Myers Squibb joined in an extension. Note: Closed in July 2025, announced in April 2026. Source

7. Encoded Therapeutics: $275M, Series F

In short: Gene therapy developer targeting Dravet syndrome and other neurological disorders. On September 9, 2026 it announced a $275M Series F. Lead investor: GV. Other investors in the round include ARCH Venture Partners, RTW Investments, SoftBank Vision Fund 2, Venrock and Farallon Capital Management. Note: The co-leading healthcare fund was not named. Source

8. Anagram Therapeutics: $250M, No series named

In short: Developing an oral enzyme pill for pancreatic insufficiency in cystic fibrosis. On May 7, 2026 it announced a $250M round. Lead investor: Blackstone Life Sciences. Note: Blackstone Life Sciences is the only investor; no series named. Source

9. Solstice Oncology: $225M, Series A

In short: Oncology biotech developing next-generation anti-CTLA-4 antibody porustobart. On September 8, 2026 it announced a $225M Series A. Lead investor: RA Capital Management. Other investors in the round include Canaan Partners and Forbion. Source

10. CellCentric: $220M, Series D

In short: Cambridge biotech developing oral p300/CBP inhibitor inobrodib for multiple myeloma. On May 6, 2026 it announced a $220M Series D. Lead investor: Venrock Healthcare Capital Partners. Other investors in the round include Fidelity Management & Research, Sofinnova Partners, HBM Healthcare Investments, RA Capital Management and Pfizer. Source

Europe

Biotech rounds we verified in Europe (companies based in Europe or the UK):

• Isomorphic Labs (UK), $2.1B, Series B: number 1 on the list.
• CellCentric (UK), $220M, Series D: number 10 on the list.

Europe's most health-focused funds in the getfund catalog

21 of the 72 most active funds in Spain, Italy and the UK are in the getfund catalog.

For Turkish founders

29 Turkey-based investors in the getfund catalog invest in health tech or biotech.

Known to lead rounds: Entertech VCIF and Sankonline.

The others: Agesa Emeklilik Teknoloji GSYF, Albaraka Garaj, Bilişim Vadisi GSYF, Cleantech Ventures, Development ODTÜ TEKNOKENT VCIF (Invest101), Eksim Ventures, Escort Teknoloji Yatırım, Fark Labs, Founder One, idacapital, Istanbul Portfoy, İTK Ventures, Kültepe GSYF, Kuveyt Türk Kobi VCIF, Maxis Girişim, OYAK Portföy Beşinci Girişim Sermayesi Yatırım Fonu, Piramit Portföy Yönetimi A.Ş., Sabancı Ventures, Sparta Portföy Yönetimi, String Ventures, Sustain Tech, T3 Girişim Sermayesi Yatırım Fonu (T3 GSYF), Teknopark Istanbul Yüksek Teknoloji GSYF, TKYB Sermaye Fonu, TRAngels, Trustlife Ventures and Tulpar Angel Investment.

Who put in the money?

Investors in more than one of these 10 rounds (in brackets: led that round):

• RA Capital, 3 rounds: Ollin Biosciences, Solstice Oncology (lead), CellCentric
• Thrive Capital, 3 rounds: Isomorphic Labs (lead), NewLimit, Chai Discovery
• ARCH Venture Partners, 2 rounds: Ollin Biosciences (lead), Encoded Therapeutics
• Bain Capital, 2 rounds: AdvanCell, Beeline Medicines (lead)
• Fidelity Management & Research, 2 rounds: AdvanCell, CellCentric
• GV, 2 rounds: Isomorphic Labs, Encoded Therapeutics (lead)
• Kleiner Perkins, 2 rounds: NewLimit, Chai Discovery
• Venrock, 2 rounds: Encoded Therapeutics, CellCentric (lead)

Raising for a health startup?

getfund matches you with the investors, accelerators and grants that fit your sector and stage.

All 2026 data and funds: getfund.space/en/funding-stats

Source: Venture Funding Database 2026 (Nikolai Aleksandrov), checks by getfund